JP2023539154A5 - - Google Patents
Info
- Publication number
- JP2023539154A5 JP2023539154A5 JP2023512354A JP2023512354A JP2023539154A5 JP 2023539154 A5 JP2023539154 A5 JP 2023539154A5 JP 2023512354 A JP2023512354 A JP 2023512354A JP 2023512354 A JP2023512354 A JP 2023512354A JP 2023539154 A5 JP2023539154 A5 JP 2023539154A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- administering
- effective amount
- intravenous solution
- solution according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2012954.0A GB202012954D0 (en) | 2020-08-19 | 2020-08-19 | Etoposide toniribate formulation |
| GBGB2012956.5A GB202012956D0 (en) | 2020-08-19 | 2020-08-19 | Etoposide toniribate formulation |
| GB2012954.0 | 2020-08-19 | ||
| GB2012956.5 | 2020-08-19 | ||
| PCT/EP2021/073034 WO2022038226A1 (en) | 2020-08-19 | 2021-08-19 | Etoposide toniribate formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539154A JP2023539154A (ja) | 2023-09-13 |
| JP2023539154A5 true JP2023539154A5 (cg-RX-API-DMAC7.html) | 2024-08-27 |
Family
ID=80322580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512354A Pending JP2023539154A (ja) | 2020-08-19 | 2021-08-19 | エトポシドトニリベート製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230398069A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4199933A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023539154A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230131815A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021327164A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3189720A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022038226A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4233837A1 (en) * | 2022-02-24 | 2023-08-30 | CellAct Pharma GmbH | Solid and oral etoposide toniribate compositions |
| CN116983259A (zh) * | 2023-09-27 | 2023-11-03 | 成都瑞尔医药科技有限公司 | 一种依托泊苷注射液的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69431071T2 (de) * | 1993-12-29 | 2003-03-20 | Matrix Pharma | Zusammensetzung für lokale freigabe von zytostatika |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| ES2354065T3 (es) * | 2001-12-03 | 2011-03-09 | Universitätsklinikum Charité Der Humboldt- Universität Zu Berlin | Podofilotoxinas en calidad de agentes antiproliferativos. |
| JP4020256B2 (ja) * | 2003-05-23 | 2007-12-12 | 日本化薬株式会社 | 前立腺癌の局所治療剤 |
| EP2308467A3 (en) * | 2005-06-17 | 2011-06-22 | Hospira Australia Pty Ltd | Liquid pharmaceutical formulations of docetaxel |
| US9889147B2 (en) * | 2010-04-16 | 2018-02-13 | Cellact Pharma Gmbh | Analogues of etoposide for the treatment of tumours |
| LT3228319T (lt) * | 2011-04-28 | 2020-09-25 | Oncopeptides Ab | Liofilizuotas citotoksinių dipeptidų preparatas |
| SI3228319T1 (sl) * | 2011-04-28 | 2020-10-30 | Oncopeptides Ab | Liofiliziran pripravek citotoksičnih dipeptidov |
| GB2513299A (en) * | 2013-03-12 | 2014-10-29 | Cellact Pharma Gmbh Biomedizinzentrum | Compounds for targeting cancer stem cells |
-
2021
- 2021-08-19 KR KR1020237009044A patent/KR20230131815A/ko active Pending
- 2021-08-19 US US18/022,353 patent/US20230398069A1/en active Pending
- 2021-08-19 AU AU2021327164A patent/AU2021327164A1/en active Pending
- 2021-08-19 EP EP21765900.2A patent/EP4199933A1/en active Pending
- 2021-08-19 WO PCT/EP2021/073034 patent/WO2022038226A1/en not_active Ceased
- 2021-08-19 JP JP2023512354A patent/JP2023539154A/ja active Pending
- 2021-08-19 CA CA3189720A patent/CA3189720A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541432A5 (cg-RX-API-DMAC7.html) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2013155188A5 (cg-RX-API-DMAC7.html) | ||
| JP2016034978A5 (cg-RX-API-DMAC7.html) | ||
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| JP2020530857A5 (cg-RX-API-DMAC7.html) | ||
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| JP2013541583A5 (cg-RX-API-DMAC7.html) | ||
| JP2016510326A5 (cg-RX-API-DMAC7.html) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| JP2020523356A5 (cg-RX-API-DMAC7.html) | ||
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| JP2016519107A5 (cg-RX-API-DMAC7.html) | ||
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| JP2018522028A5 (cg-RX-API-DMAC7.html) | ||
| MX2017011169A (es) | Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro. | |
| JP2022532038A5 (cg-RX-API-DMAC7.html) | ||
| JP2019529569A5 (cg-RX-API-DMAC7.html) | ||
| WO2017013490A3 (en) | Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer | |
| JP2018516920A5 (cg-RX-API-DMAC7.html) | ||
| KR20220083020A (ko) | 알츠하이머병을 동반한 혈관성 치매를 치료하는 약제학적 복합제제 | |
| JP2010519274A5 (cg-RX-API-DMAC7.html) | ||
| RU2020123217A (ru) | Противо-SARS-CoV-2 вирусное средство Антипровир |